Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Trial of naproxen and celecoxib suspended

Use of study drugs in a large, federally funded Alzheimer prevention trial has been suspended following a decision by the study's leadership on Dec. 17, 2004.

9 Jan 2005

Functional magnetic resonance imaging helps visualize the human brain as a massive, interacting, complex network

A team headed by scientists at Northwestern University, using functional magnetic resonance imaging (fMRI), has shown how to visualize the human brain as a massive, interacting, complex network governed by a few underlying dynamic principles.

5 Jan 2005

Indian curry may be the next Alzheimer's weapon

A dietary staple of India, where Alzheimer's disease rates are reportedly among the world's lowest, holds potential as a weapon in the fight against the disease.

28 Dec 2004

Paclitaxel may benefit Alzheimer's and Parkinson's movement disorders

Angiotech Pharmaceuticals have announced that a preclinical study published in today's early edition of the Proceedings of the National Academy of Sciences highlights the positive effects of Paxceed on movement disorders commonly seen in diseases known as taupathies, such as Alzheimer's and Parkinson's.

27 Dec 2004

Public health advisory for the use of non-steroidal anti-inflammatory drug products

The Food and Drug Administration (FDA) has issued a Public Health Advisory summarizing the agency's recent recommendations concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs), including those known as COX-2 selective agents.

23 Dec 2004

Turning off cell suicide switch fails to stop prion damage

Researchers knew that prions, the misfolded proteins that cause mad cow disease and other brain disorders, were killing off a class of important brain cells in a transgenic mouse model. But when they found a way to rescue those cells, they were astonished to discover the mice still became sick.

21 Dec 2004

No increased cardiovascular risk seen in elderly patients taking Celebrex

The National Institutes of Health has reported in an Alzheimer's Disease prevention study that there was no increased cardiovascular risk seen in elderly patients taking Celebrex (400 mg daily) for up to three years.

21 Dec 2004

Theory that could help to cure diseases including cancer

An Open University science student has astonished the world of medicine with a theory that could help to cure diseases including cancer.

21 Dec 2004

Biological clock affects the patterns of heart-rate control in healthy individuals

In a newly reported, first-ever finding, physicists from Boston University and physiologists from Boston’s Brigham and Women’s Hospital (BWH) have found that the body’s biological clock affects the patterns of heart-rate control in healthy individuals independent of sleep/wake cycle or other behavior influences.

21 Dec 2004

Cancer drug paclitaxel may reduce the adverse effects of Alzheimer's disease

In a preclinical efficacy trial, the cancer drug paclitaxel (Paxceed)–which exerts its effects by binding to and stabilizing microtubules inside cells–reduced the adverse effects of Alzheimer's disease (AD)-like pathology in a mouse model.

20 Dec 2004

FDA issues advice on Naproxen

The FDA has released the following statement on NIH halting a clinical trial involving non-steroidal anti-inflammatory drugs in patients at risk of developing Alzheimer's Disease:

20 Dec 2004

Celebrex suspension

The National Institutes of Health (NIH) announced that it has suspended the use of COX-2 inhibitor celecoxib (Celebrex™ Pfizer, Inc.) for all participants in a large colorectal cancer prevention clinical trial conducted by the National Cancer Institute (NCI).

19 Dec 2004

Annual decline in cognitive functioning is similar in patients with Parkinson disease and dementia and patients with Alzheimer disease

The average annual decline in cognitive functioning is similar in patients with Parkinson disease (PD) and dementia and patients with Alzheimer disease (AD), according to an article in the December issue of The Archives of Neurology, one of the JAMA/Archives journals.

13 Dec 2004

Odor identification test, strong predictor of Alzheimer's Disease

The inability to identify the smell of lemons, lilac, leather and seven other odors predicts which patients with minimal to mild cognitive impairment (MMCI) will develop Alzheimer's Disease, according to a study presented today at the American College of Neuropsychopharmacology (ACNP) annual meeting.

13 Dec 2004

Trimming fat overcomes one of the major obstacles to drug design

Biochemists at Ohio State University and their colleagues have overcome one of the major obstacles to drug design, by trimming some of the fat from a molecular sponge that scientists use to study proteins.

8 Dec 2004

Neurobiologists distinguish in unprecedented detail the patterns of brain activity

Using hairlike microelectrodes and computer analysis, neurobiologists at Duke University Medical Center have demonstrated that they can see the detailed instant-to-instant electrical "brainscape" of neural activity across a living brain.

8 Dec 2004

Important genetic risk factor for amyotrophic lateral sclerosis

Two Hershey, Pa., researchers were part of a team that has uncovered what may be an important genetic risk factor for amyotrophic lateral sclerosis (ALS).

6 Dec 2004

Episome vectors offer fresh angle to gene therapy

A European research team is seeking to overcome the early setbacks suffered by the promising new field of ‘gene therapy’ by developing a revolutionary delivery technique, known as ‘episome vectors’. This breakthrough could pave the way to treating hereditary diseases by injecting the body with healthy versions of damaged genes.

6 Dec 2004

A vitamin B pill that drastically lowers blood levels of homocysteine could one day be used to prevent dementia

High blood levels of homocysteine are a risk factor for stroke and dementia, including Alzheimer’s disease. Raised levels damage nerves and blood vessels, and lead to a loss of brain tissue in patients.

4 Dec 2004

Toxic proteins explain memory loss in Alzheimer's patients

Researchers at Northwestern University have discovered a molecular mechanism -- a tiny protein attacking nerve cells -- that could explain why the brain damage in early Alzheimer's disease results in memory loss and not other symptoms such as loss of balance or tremors.

1 Dec 2004